The most common adverse events of grade 3 or 4 were neutropenia ( 120 [ 95 % ] in the etoposide plus cisplatin group vs 101 [ 78 % ] in the irinotecan plus cisplatin group ) , anaemia ( 44 [ 35 % ] vs 50 [ 39 % ] ) , thrombocytopenia ( 26 [ 21 % ] vs six [ 5 % ] ) , febrile neutropenia ( 21 [ 17 % ] vs 18 [ 14 % ] ) , and diarrhoea ( two [ 2 % ] vs 13 [ 10 % ] ) .